Foreign Media: Can China Maintain Its Rapid Development in Cancer Drug Innovation?
China is rapidly rising as a global leader in cancer drug research and development, occupying significant shares in areas such as antibody-drug conjugates (51% globally), bispecific antibodies (48%), and CAR-T therapy (48%). Between 2023 and 2024, nearly 30% of the licensed molecules from major multinational pharmaceutical companies came from China, compared to 0% six years ago.
Kangcheng Biopharma's bispecific antibody, Ivacitinib (targeting PD-1 and VEGF), showed better progression-free survival than Keytruda in China's Phase III lung cancer trial, which could become a turning point. If the results of its U.S. trial (expected to be completed by December 2025) are consistent, it will significantly promote the internationalization of Chinese anti-cancer drugs.
Although Chinese pharmaceutical companies initially relied on Western service providers, they have gradually developed independent R&D capabilities. 75% of Chinese pharmaceutical companies are currently in clinical stages, higher than 64% in the United States.
Original article: https://www.toutiao.com/article/1836595551958148/
Statement: This article represents the views of the author alone.